
About Kupffer Biotherapeutics
Kupffer Biotherapeutics was a Healthcare company based in Burlingame (United States) founded in 2019. It develops innovative technologies for anticancer therapies targeting gastrointestinal cancers. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Biotechnology, Oncology and Anticancer Therapy. Its competitors include Ironwood Pharma, Ardelyx and Alcresta; 3 of its 3 listed competitors have raised funding.
Company details
Kupffer Biotherapeutics, based in Burlingame, focuses on providing healthcare solutions, advancing biotech innovations, oncology, and anticancer therapy. Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Burlingame, United States
- SectorsHealthcare
- Website kupfferbio.com
Competitors of Kupffer Biotherapeutics
Kupffer Biotherapeutics has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Ardelyx and Alcresta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. |
Detailed competitors of Kupffer Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Kupffer Biotherapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kupffer Biotherapeutics
Kupffer Biotherapeutics was founded in 2019.
Kupffer Biotherapeutics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Kupffer Biotherapeutics, based in Burlingame, focuses on providing healthcare solutions, advancing biotech innovations, oncology, and anticancer therapy. Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Kupffer Biotherapeutics's top competitors include Ironwood Pharma, Ardelyx and Alcresta.